116 related articles for article (PubMed ID: 12778354)
21. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
22. [Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma].
Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Hegenbart U; Irngartinger G; Oberdorfer F; van Kaick G
Radiologe; 1997 Jan; 37(1):74-80. PubMed ID: 9157479
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
[TBL] [Abstract][Full Text] [Related]
25. FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up.
Amthauer H; Furth C; Denecke T; Hundsdoerfer P; Voelker T; Seeger K; Stöver B; Henze G
Klin Padiatr; 2005; 217(6):327-33. PubMed ID: 16307418
[TBL] [Abstract][Full Text] [Related]
26. Whole body positron emission tomography in the treatment of Hodgkin disease.
Hueltenschmidt B; Sautter-Bihl ML; Lang O; Maul FD; Fischer J; Mergenthaler HG; Bihl H
Cancer; 2001 Jan; 91(2):302-10. PubMed ID: 11180075
[TBL] [Abstract][Full Text] [Related]
27. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease.
Weihrauch MR; Re D; Bischoff S; Dietlein M; Scheidhauer K; Krug B; Textoris F; Ansén S; Franklin J; Bohlen H; Wolf J; Schicha H; Diehl V; Tesch H
Ann Hematol; 2002 Jan; 81(1):20-5. PubMed ID: 11807631
[TBL] [Abstract][Full Text] [Related]
28. FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial.
Lopci E; Mascarin M; Piccardo A; Castello A; Elia C; Guerra L; Borsatti E; Sala A; Todesco A; Zucchetta P; Farruggia P; Cistaro A; Buffardi S; Bertolini P; Bianchi M; Moleti ML; Bunkheila F; Indolfi P; Fagioli F; Garaventa A; Burnelli R;
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):97-106. PubMed ID: 30219963
[TBL] [Abstract][Full Text] [Related]
29. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
[TBL] [Abstract][Full Text] [Related]
30. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
31. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
32. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
[TBL] [Abstract][Full Text] [Related]
34. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease.
Advani R; Maeda L; Lavori P; Quon A; Hoppe R; Breslin S; Rosenberg SA; Horning SJ
J Clin Oncol; 2007 Sep; 25(25):3902-7. PubMed ID: 17664458
[TBL] [Abstract][Full Text] [Related]
35. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
36. FDG-PET in the detection of residual disease and relapse in patients with Hodgkin's lymphoma. Experience from a Swedish centre.
Bjurberg M; Gustavsson A; Ohlsson T; Brun E
Acta Oncol; 2006; 45(6):743-9. PubMed ID: 16938818
[TBL] [Abstract][Full Text] [Related]
37. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial.
Furth C; Steffen IG; Amthauer H; Ruf J; Misch D; Schönberger S; Kobe C; Denecke T; Stöver B; Hautzel H; Henze G; Hundsdoerfer P
J Clin Oncol; 2009 Sep; 27(26):4385-91. PubMed ID: 19667276
[TBL] [Abstract][Full Text] [Related]
38. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease.
Furth C; Denecke T; Steffen I; Ruf J; Voelker T; Misch D; Vondran F; Plotkin M; Stöver B; Henze G; Lemke AJ; Amthauer H
J Pediatr Hematol Oncol; 2006 Aug; 28(8):501-12. PubMed ID: 16912590
[TBL] [Abstract][Full Text] [Related]
39. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
[TBL] [Abstract][Full Text] [Related]
40. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
Kurch L; Hasenclever D; Kluge R; Georgi T; Tchavdarova L; Golombeck M; Sabri O; Eggert A; Brenner W; Sykora KW; Bengel FM; Rossig C; Körholz D; Schäfers M; Feuchtinger T; Bartenstein P; Ammann RA; Krause T; Urban C; Aigner R; Gattenlöhner S; Klapper W; Mauz-Körholz C
Pediatr Blood Cancer; 2019 Mar; 66(3):e27539. PubMed ID: 30426671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]